Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions

Innovating targeting

Innovating targeting

Philogen is pleased to invite you to a new webinar on July 10, 2024, at 14:00 GMT | 15:00 CET.

Submission of NidlegyTM Marketing Authorization Application Validated by EMA

Nidlegy™ Marketing Authorization Application Submitted to EMA

Richiesta di autorizzazione all’immissione in commercio per il prodotto Nidlegy™ sottomessa all’EMA

Risultati dello studio clinico di Fase III PIVOTAL di Nidlegy nel melanoma da presentare all’ASCO 2024

Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024

Deposito del Verbale dell’Assemblea degli Azionisti

Philogen to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024.

Philochem to attend as Lecturer to the Summer School in Pharmaceutical Analysis 2024 in Rimini on September 18-20, 2024

The Board of Directors approves the Net Financial Position for the First Quarter of 2024

OUR SCIENCES

PIPELINE

WORK WITH US